Cargando…

P18-14 LB. Vacc-4x HIV p24-like peptide vaccine-associated increase of CD4 T-cells in chronically infected HIV-1 patients on antiretroviral therapy

Detalles Bibliográficos
Autores principales:	Bengtsson, P, Baksaas, I, Sommerfelt, M, Sörensen, B, Kvale, D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767930/ http://dx.doi.org/10.1186/1742-4690-6-S3-P413

Ejemplares similares

Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial
por: Brekke, Kristin, et al.
Publicado: (2014)

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine
por: Ellefsen-Lavoie, K, et al.
Publicado: (2012)

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
por: Brekke, Kristin, et al.
Publicado: (2017)

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption
por: Rockstroh, Jürgen K., et al.
Publicado: (2019)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

VaccImm: simulating peptide vaccination in cancer therapy
por: von Eichborn, Joachim, et al.
Publicado: (2013)

P18-13 LB. Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals
por: Yassine Diab, B, et al.
Publicado: (2009)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
por: Bakari, M, et al.
Publicado: (2009)

P07-11 LB. Impact of highly active antiretroviral therapy on cell-free and cell-associated HIV-1 in cervicovaginal secretions and blood
por: Rubbo, P, et al.
Publicado: (2009)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

P12-14. Design of hydrophilic, helical peptides that mimic the 4E10 epitope of HIV-1 gp41
por: Lorenz, IC, et al.
Publicado: (2009)

Comparative study on use of CD4 T cell count and plasma P24 antigen concentration in antiretroviral therapy monitoring for HIV/AIDs patients in Kano, Nigeria
por: Yahaya, Abdulrazak, et al.
Publicado: (2006)

LB5. Safety of In Utero Antiretroviral (ARV) Exposure: Neurologic Outcomes in HIV-Exposed, Uninfected Children
por: Crowell, Claudia S, et al.
Publicado: (2018)

HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens
por: Tagliamonte, Maria, et al.
Publicado: (2012)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
por: Hamilton, Kyra, et al.
Publicado: (2022)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

P16-55 LB. The role of CD4+ CD25+ regulatory T cells in the control of IL-10 mediated T cell impairment in chronic HIV Infection
por: Kwon, DS, et al.
Publicado: (2009)

P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level
por: Bunnik, EM, et al.
Publicado: (2009)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
por: Franchini, G
Publicado: (2009)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
por: Radonjic-Simic, Mirjana, et al.
Publicado: (2021)

HIV‐free survival at 12–24 months in breastfed infants of HIV‐infected women on antiretroviral treatment
por: Chikhungu, Lana Clara, et al.
Publicado: (2016)

HIV virological non-suppression is highly prevalent among 18- to 24-year-old youths on antiretroviral therapy at the Kenyan coast
por: Nyongesa, Moses K., et al.
Publicado: (2022)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

Strategy for Identifying Dendritic Cell-Processed CD4(+) T Cell Epitopes from the HIV Gag p24 Protein
por: Bozzacco, Leonia, et al.
Publicado: (2012)

Development of Immune-Specific Interaction Potentials and Their Application in the Multi-Agent-System VaccImm
por: Woelke, Anna Lena, et al.
Publicado: (2011)

Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

P17-28 LB. The antiviral efficacy of HIV-specific CD8+ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate
por: Ranasinghe, S, et al.
Publicado: (2009)

Production of HIV-1 p24 protein in transgenic tobacco plants
por: Zhang, G. Gary, et al.
Publicado: (2002)

P04-54 LB. Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals
por: Gnanakaran, G, et al.
Publicado: (2009)

OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission
por: Lingappa, JR, et al.
Publicado: (2009)

P16-14. Loss of balance between CD4+ regulatory T cell and Th17 population in chronic HIV infection
por: Li, D, et al.
Publicado: (2009)

The investigation of CD4(+)T-cell functions in primary HIV infection with antiretroviral therapy
por: Sun, Yu, et al.
Publicado: (2017)

HIV-associated benign lymphoepithelial cysts of the parotid glands confirmed by HIV-1 p24 antigen immunostaining
por: Sekikawa, Yoshiyuki, et al.
Publicado: (2017)

2509: Estimation of HIV viral load using quantitative measurement of HIV-p24 on lateral flow immunoassays
por: Conrad, Joseph A., et al.
Publicado: (2018)

2,4-Dichloro-N-p-tolylbenzamide
por: Saeed, Aamer, et al.
Publicado: (2009)

Cost-Effectiveness of Early Infant HIV Diagnosis of HIV-Exposed Infants and Immediate Antiretroviral Therapy in HIV-Infected Children under 24 Months in Thailand
por: Collins, Intira Jeannie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_me5fal7gabq94c3ao4j4bneh6k